Cycle Pharmaceuticals proposes $466m acquisition of Vanda Pharmaceuticals
In a significant development within the pharmaceutical industry, UK-based Cycle Pharmaceuticals has offered to acquire Nasdaq-listed Vanda Pharmaceuticals in an all-cash transaction valued at $466 million. Under this proposal, Cycle Pharmaceuticals plans to purchase shares of Vanda Pharmaceuticals at $8 per share, representing a substantial premium over recent closing prices. Financial Details and Premiums Offered […]